Search research articles
Contact Us
Filters
Showing results (91-100 of 110) with videos related to
Page
of 11
Sort By:
American Journal of Clinical Oncology
|
February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Roger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancers
David S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
JCO Precision Oncology
|
October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology
Patricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
The Lancet. Oncology
|
April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Investigational New Drugs
|
June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
BMJ Supportive & Palliative Care
|
August 30, 2022
PALLIA 10 score in phase I cancer studies
Kaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 110) with videos related to
Sort By:
Page
of 11
American Journal of Clinical Oncology
|
February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Roger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
Journal for Immunotherapy of Cancer
|
June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancers
David S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
JCO Precision Oncology
|
October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology
Patricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
The Lancet. Oncology
|
April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Investigational New Drugs
|
June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
BMJ Supportive & Palliative Care
|
August 30, 2022
PALLIA 10 score in phase I cancer studies
Kaïssa Ouali, Christine Mateus, Arianne Laparra, et al.
Page
of 11